NASDAQ:IMVT Immunovant Q1 2026 Earnings Report $39.25 +0.13 (+0.33%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Immunovant EPS ResultsActual EPS-$0.60Consensus EPS -$0.69Beat/MissBeat by +$0.09One Year Ago EPS-$0.60Immunovant Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmunovant Announcement DetailsQuarterQ1 2026Date8/11/2025TimeBefore Market OpensConference Call DateMonday, August 11, 2025Conference Call Time7:00AM ETUpcoming EarningsImmunovant's Q2 2027 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunovant Earnings HeadlinesImmunovant Shareholders Back Board, Auditor and Executive PaySeptember 3 at 6:31 PM | tipranks.comImmunovant's Risk/Reward Profile Balanced After Recent Rally, UBS SaysAugust 24, 2026 | finance.yahoo.comHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors. | SmartAsset (Ad)Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmAugust 19, 2026 | prnewswire.comImmunovant (IMVT) Receives a Buy from OppenheimerAugust 13, 2026 | theglobeandmail.comImmunovant (IMVT) Q1 2027 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comSee More Immunovant Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunovant? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunovant and other key companies, straight to your email. Email Address About ImmunovantImmunovant (NASDAQ:IMVT) Inc. is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia. The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG. Efgartigimod is being evaluated in late-stage clinical trials for generalized myasthenia gravis and other indications, and has demonstrated the potential to provide rapid and durable reductions in pathogenic IgG levels. In addition to efgartigimod, Immunovant is advancing a pipeline of next-generation FcRn-targeted monoclonal antibodies designed to address a range of antibody-mediated diseases. Founded in 2017 as a spin-out of Roivant Sciences, Immunovant is headquartered in New York, with research and development activities spanning North America and Europe. The company’s clinical programs involve global trial sites across key regions, and its leadership team comprises experienced executives and scientists with deep expertise in immunology and biologics development. Immunovant continues to collaborate with academic institutions and strategic partners to advance its FcRn-focused platform toward regulatory approval and commercial readiness.View Immunovant ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story3 Stocks With September Catalysts Investors Shouldn’t IgnoreOllie's Bargain Outlet Stock Falls on Weak Comps Despite Margin GainsWhy Hewlett Packard Enterprise’s Sell-Off May Not LastSnowflake’s AI Momentum Is Forcing a Fresh Look at the Stock Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
